Clinical Trials
4 trialsNCT00326885 2018-10-17
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Neovii Biotech
Phase 2 Completed
NCT01320020 2013-07-02
A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Neovii Biotech
Phase 1 Terminated
NCT00822809 2012-10-03
CASIMAS
Neovii Biotech
Phase 3 Completed
NCT00377429 2012-07-19
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
Neovii Biotech
Phase 2 Completed